As Erleada, a prostate cancer treatment, has received mandatory reimbursement since last April, attention is focusing on whether the co-payment ratio for Xtandi and Zytiga in the same class will be reduced. Currently, Erleada receives mandatory benefits with a co-payment of 5%, and Xtandi·Zytiga receives 30% screening benefits.

The Cancer Disease Review Committee of the Health Insurance Review and Assessment Service held the 4th meeting in 2023 on the 14th and decided to reduce the co-payment rate for Xtandi and Zytiga. Earlier in April, Janssen Korea's Erleada was listed as a mandatory benefit with a co-payment rate of 5% for the first time in the Androgen receptor targeted agent series. Accordingly, the